



## Online resource 1



**Online resource 1:** The figure depicts the treatment schedule with time points for vaccination (# = vaccine number) and clinical and immune evaluation.

Concomitant treatment include: Cyclophosphamide (line) 50 mg twice a day every 2<sup>nd</sup> week, Celecoxib (dotted line) 200 mg daily and Interleukin-2 (squares), 2 MIU given as subcutaneous injections day 1-5 after each vaccination except the first.

Online resource 2



**Online resource 2:** Fifty-eight patients were screened for inclusion, 29 patients were included and 25 patients were fully evaluable. The flow diagram depicts the details. Numbers in brackets illustrate the number of patients. PS=Performance Status

### Online resource 3

Patient no	Peptides / tumor lysate
101,104,106,112,117,127,134,136,138	allogeneic tumor lysate (melanoma cell lines VM 115, COLO 829, SK-MEL-28)
102,116	autologous tumor lysate
103,126	sur(1M2, 9, 18-28, 6-14) hTert(p865, p540, p572, p30, p988, p672, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
113,139	sur(1M2, 9, 18-28, 93-101, 47-56, 92-101) hTert(p865, p540, p572, p30, p988, p672, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
118	sur(1M2, 9, 18-28, 93-101, 47-56, 92-101) hTert(p865, p540, p572, p30, p988, p672), Padre
119	sur(1M2, 9, 18-28, 18-27) hTert(p865, p540, p572, p30, p988, p672, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
120	sur(1M2, 9, 18-28) hTert(p865, p540, p572, p30, p988, p672, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
121,128	sur(1M2, 9, 18-28, 6-14) hTert(p865, p540, p572, p30, p988, p672, p766) Padre
123	sur(1M2, 9, 18-28, 93-101, 47-56, 92-101) hTert(p865, p540, p572, p30, p988, p672) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
125	sur(1M2, 9, 18-28, 18-27, 6-14) hTert(p865, p540, p572, p30, p988, p973, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
129	sur(1M2, 9, 18-28, 53-62) hTert(p865, p540, p572, p30, p988, p672, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
130	sur(1M2, 9, 18-28, 18-27, 6-14) hTert(p865, p540, p572, p30, p988, p672, p973, p766) Padre
131	sur(1M2, 9, 18-28, 93-101, 47-56, 92-101) hTert(p865, p540, p572, p30, p988, p672, p766) Padre
132	sur(1M2, 9, 18-28) hTert(p865, p540, p572, p30, p988, p672, p766) Padre
133	sur(1M2, 9, 18-28, 18-27, 6-14) hTert(p865, p540, p572, p30, p988, p672, p766) Padre
135	sur(1M2, 9, 18-28, 6-14) hTert(p865, p540, p572, p30, p988) R9V, L9V, G11V, S9V, K9V, Y9L, Padre
140	sur(1M2, 9, 18-28, 53-62, 6-14) hTert(p865, p540, p572, p30, p988, p672, p766) R9V, L9V, G11V, S9V, K9V, Y9L, Padre

**Online resource 3:** Patients received dendritic cells pulsed with tumor lysate or peptides according to their HLA type. The number of peptides depend on the HLA-type of the patient and whether the tumor did express p53 (primary or metastatic lesion tested for p53 expression with immunohistochemistry).